AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 14 - (NewsRx.com & NewsRx.net) -- With some 2.5 million deaths and 9 million new cases annually, tuberculosis (TB), along with HIV/AIDS, is responsible for the greatest number of infectious disease victims worldwide.
Of particular concern is the fact that an ever-increasing number of pathogens are becoming resistant to conventional medications. Figures from the World Health Organization indicate that some 50 million people around the globe are infected with these multidrug-resistant strains. An effective tuberculosis vaccine, therefore, is more urgently needed than ever.
A consortium of business and research centers has launched a program to develop just such a vaccine. Scientists at the Max Planck Institute for Infection Biology (MPIIB) in Berlin, under the direction of Professor Stefan H.E. Kaufmann, have developed a highly promising vaccine candidate. And now, Vakzine Projekt Management GmbH (VPM) has acquired a worldwide license for several patents from Max Planck Society. VPM was founded by Germany's Federal Ministry for Education and Research (BMBF) as part of a national vaccine initiative. In collaboration with MPIIB and the German Research Center for Biotechnology (GBF) VPM will manage the preclinical and clinical study program.
"For our new tuberculosis vaccine candidates we are relying on genetically modified variants of the live BCG vaccine that has been in use since 1921," said MPI director, Prof. Dr. Stefan Kaufmann. "The vaccine consists of an attenuated bacteria that is very closely related to the TB ...